nach oben

Advances in Gerontology

Erschienen in:

15.02.2024 | RESEARCH ARTICLES

Patterns of Expression of the Key Genes of the BDNF System and Serotonin Receptors in the Brain of OXYS Rats in the Development of the Signs of Alzheimer’s Disease

verfasst von: M. Alsallum, Ya. P. Kaminskaya, A. S. Tsybko, N. G. Kolosova, V. S. Naumenko

Erschienen in: Advances in Gerontology | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

In spite of numerous studies, pathogenesis of the sporadic (not inherited) form of Alzheimer’s disease (AD) still remains largely unclear; nevertheless, there is general consensus as regards the complex involvement of neurotrophic factors and neurotransmitters in the mechanisms of this disease. In light of recent data on the physical interaction between serotonin (5-HT) receptors and receptors of the brain-derived neurotrophic factor (BDNF), the reciprocal modulation between 5-HT and BDNF systems is of particular interest, inter alia, in the context of AD development. The OXYS lineage of prematurely aging rats is a unique model of sporadic AD. Previously, it has been reported on the changed neurotrophin balance in the brain of these animals; however, the changes in the expression of BDNF and its receptors in the dynamics of development of AD symptoms has been studied insufficiently. Even less is known about the patterns of expression of 5-HT receptors in OXYS rat brain. In the present work, we have compared the expression of BDNF and its receptors, TrkB and p75^NTR, as well as serotonin 5-НТ_1А, 5-НТ_2А, 5-НТ₄ and 5-НТ₇ receptors in the brain of OXYS and Wistar rats aged 20 days, 3.5 and 18 months. The frontal cortex of 20-day-old OXYS rats demonstrated a significant increase in the mRNA level of the Bdnf, Htr2a and Htr7 genes and, at the same time, a decrease in the ratio of phosphorylated and nonphosphorylated forms of the TrkB receptor. In the hippocampus of 20-day-old OXYS rats, the mRNA levels of the Bdnf, Htr1a, Htr2a and Htr4 genes are also elevated. A substantially higher mRNA level of the above genes for 5-HT receptors was observed in the hippocampus of OXYS rats also at the age of 3.5 months, in the period of manifestation of the first AD symptoms. The nature of change in gene expression patterns indicates the potential involvement of 5-HT receptors in suppression of the TrkB receptor function in the early period of postnatal development of OXYS rats, which may be one of the mechanisms, through which 5-HT receptors are involved in the development of pathological process in the period of manifestation of AD symptoms in OXYS rats.

Liu, R.M., Aging, cellular senescence, and Alzheimer’s disease, Int. J. Mol. Sci., 2022, vol. 23, no. 4, p. 1989. https://doi.org/10.3390/ijms23041989CrossRefPubMedPubMedCentral

Soria Lopez, J.A., González, H.M., and Léger, G.C., Alzheimer’s disease, Handb. Clin. Neurol., 2019, vol. 167, pp. 231–255. https://doi.org/10.1016/B978-0-12-804766-8.00013-3CrossRefPubMed

Zagrebelsky, M., Tacke, C., and Korte, M., BDNF signaling during the lifetime of dendritic spines, Cell Tissue Res., 2020, vol. 382, pp. 185–199. https://doi.org/10.1007/s00441-020-03226-5CrossRefPubMedPubMedCentral

Minichiello, L., TrkB signalling pathways in LTP and learning, Nat. Rev. Neurosci., 2009, vol. 10, pp. 850–860. https://doi.org/10.1038/nrn2738CrossRefPubMed

Ibrahim, A.M., Chauhan, L., Bhardwaj, A., et al., Brain-derived neurotropic factor in neurodegenerative disorders, Biomedicines, 2022, vol. 10. https://doi.org/10.3390/biomedicines10051143

Allen, S.J., Watson, J.J., Shoemark, D.K., et al., GDNF, NGF and BDNF as therapeutic options for neurodegeneration, Pharmacol. Ther., 2013, vol. 138, pp. 155–175. https://doi.org/10.1016/j.pharmthera.2013.01.004CrossRefPubMed

Invernizzi, S., Simoes Loureiro, I., Kandana Arachchige, K.G., and Lefebvre, L., Late-life depression, cognitive impairment, and relationship with Alzheimer’s disease, Dement. Geriatr. Cogn. Disord., 2022, vol. 50, pp. 414–424. https://doi.org/10.1159/000519453CrossRef

Roux, C.M., Leger, M., and Freret, T., Memory disorders related to hippocampal function: The interest of 5‑HT(4)Rs targeting, Int. J. Mol. Sci., 2021, vol. 22, no. 21, p. 12082. https://doi.org/10.3390/ijms222112082CrossRefPubMedPubMedCentral

Nirogi, R., Jayarajan, P., Shinde, A., et al., Progress in investigational agents targeting serotonin-6 receptors for the treatment of brain disorders, Biomolecules, 2023, vol. 13, no. 2, p. 309. https://doi.org/10.3390/biom13020309CrossRefPubMedPubMedCentral

10.

Jiang, S., Sydney, E.J., Runyan, A.M., et al., 5-HT4 receptor agonists treatment reduces tau pathology and behavioral deficit in the PS19 mouse model of tauopathy, Preprint of bioRxiv Prepr. Serv. Biol., 2023. https://doi.org/10.1101/2023.02.03.526871

11.

Labus, J., Röhrs, K.-F., Ackmann, J., et al., Amelioration of tau pathology and memory deficits by targeting 5-HT7 receptor, Prog. Neurobiol., 2021, vol. 197, p. 101900. https://doi.org/10.1016/j.pneurobio.2020.101900CrossRefPubMed

12.

Jahreis, K., Brüge, A., Borsdorf, S., et al., Amisulpride as a potential disease-modifying drug in the treatment of tauopathies, Alzheimers Dement., 2023. https://doi.org/10.1002/alz.13090

13.

Popova, N.K. and Naumenko, V.S., Neuronal and behavioral plasticity: The role of serotonin and BDNF systems tandem, Expert Opin. Ther. Targets, 2019, vol. 23, pp. 227–239. https://doi.org/10.1080/14728222.2019.1572747CrossRefPubMed

14.

Homberg, J.R., Molteni, R., Calabrese, F., and Riva, M.A., The serotonin–BDNF duo: Developmental implications for the vulnerability to psychopathology, Neurosci. Biobehav. Rev., 2014, vol. 43, pp. 35–47. https://doi.org/10.1016/j.neubiorev.2014.03.012CrossRefPubMed

15.

Ilchibaeva, T., Tsybko, A., Zeug, A., et al., Serotonin receptor 5-HT2A regulates TrkB receptor function in heteroreceptor complexes, Cells, 2022, vol. 11. https://doi.org/10.3390/cells11152384

16.

Stefanova, N.A., Muraleva, N.A., Korbolina, E.E., et al., Amyloid accumulation is a late event in sporadic Alzheimer’s disease-like pathology in nontransgenic rats, Oncotarget, 2015, vol. 6, pp. 1396–1413. https://doi.org/10.18632/oncotarget.2751CrossRefPubMed

17.

Stefanova, N.A., Maksimova, K.Y., Kiseleva, E., et al., Melatonin attenuates impairments of structural hippocampal neuroplasticity in OXYS rats during active progression of Alzheimer’s disease-like pathology, J. Pineal Res., 2015, vol. 59, pp. 163–177. https://doi.org/10.1111/jpi.12248CrossRefPubMed

18.

Rudnitskaya, E.A., Kolosova, N.G., and Stefanova, N.A., Impact of changes in neurotrophic supplementation on development of Alzheimer’s disease-like pathology in OXYS rats, Biochem., 2017, vol. 82, pp. 318–329. https://doi.org/10.1134/S0006297917030105CrossRef

19.

Tyumentsev, M.A., Stefanova, N.A., Muraleva, N.A., et al., Mitochondrial dysfunction as a predictor and driver of Alzheimer’s disease-like pathology in OXYS rats., J. Alzheimers. Dis., 2018, vol. 63, pp. 1075–1088. https://doi.org/10.3233/JAD-180065CrossRefPubMed

20.

Kolosova, N.G., Stefanova, N.A., and Sergeeva, S.V., OXYS rats: A prospective model for evaluation of antioxidant availability in prevention and therapy of accelerated aging and age-related cognitive decline, in Handbook of Cognitive Aging: Causes, Processes and Effects (Aging Issues, Health and Financial Alternatives Series), 2011, ISBN 9781608760282.

21.

Kulikov, A.V., Naumenko, V.S., Voronova, I.P., et al., Quantitative RT-PCR assay of 5-HT1A and 5-HT2A serotonin receptor MRNAs using genomic DNA as an external standard, J. Neurosci. Methods, 2005, vol. 141, p. 97–101. https://doi.org/10.1016/j.jneumeth.2004.06.005CrossRefPubMed

22.

Naumenko, V.S. and Kulikov, A.V., Quantitative assay of 5-HT1A receptor gene expression in the brain, Mol. Biol., 2006, vol. 40, p. 30–36. https://doi.org/10.1134/S0026893306010067/METRICSCrossRef

23.

Naumenko, V.S., Osipova, D.V., Kostina, E.V., and Kulikov, A.V., Utilization of a two-standard system in real-time PCR for quantification of gene expression in the brain, J. Neurosci. Methods, 2008, vol. 170, pp. 197–203. https://doi.org/10.1016/j.jneumeth.2008.01.008CrossRefPubMed

24.

Gao, L., Zhang, Y., Sterling, K., and Song, W., Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential, Transl. Neurodegener., 2022, vol. 11, pp. 1–34. https://doi.org/10.1186/s40035-022-00279-0CrossRef

25.

Rudnitskaya, E.A., Maksimova, K.Y., Muraleva, N.A., et al., Beneficial effects of melatonin in a rat model of sporadic Alzheimer’s disease, Biogerontology, 2015, vol. 16, pp. 303–316. https://doi.org/10.1007/s10522-014-9547-7CrossRefPubMed

26.

Rudnitskaya, E.A., Kozlova, T.A., Burnyasheva, A.O., et al., Alterations of hippocampal neurogenesis during development of Alzheimer’s disease-like pathology in OXYS rats, Exp. Gerontol., 2019, vol. 115, pp. 32–45. https://doi.org/10.1016/j.exger.2018.11.008CrossRefPubMed

27.

Rudnitskaya, E.A., Kozlova, T.A., Burnyasheva, A.O., et al., Features of postnatal hippocampal development in a rat model of sporadic Alzheimer’s disease, Front. Neurosci., 2020, vol. 14, p. 533. https://doi.org/10.3389/fnins.2020.00533CrossRefPubMedPubMedCentral

28.

Stefanova, N.A., Muraleva, N.A., Maksimova, K.Y., et al., An antioxidant specifically targeting mitochondria delays progression of Alzheimer’s disease-like pathology, Aging (Albany, New York), 2016, vol. 8, p. 2713–2733. https://doi.org/10.18632/aging.101054CrossRef

29.

Wang, Z.-H., Xiang, J., Liu, X., et al., Deficiency in BDNF/TrkB neurotrophic activity stimulates δ-secretase by upregulating C/EBPβ in Alzheimer’s disease, Cell Rep., 2019, vol. 28, pp. 655–669. https://doi.org/10.1016/j.celrep.2019.06.054CrossRefPubMedPubMedCentral

30.

Hosseini, S., Vázquez-Villegas, P., Rito-Palomares, M., and Martinez-Chapa, S.O., Enzyme-Linked Immunosorbent Assay (ELISA): From A to Z, 2018, Springer, 2018, ISBN 9789811067655.CrossRef

31.

Lorke, D.E., Lu, G., Cho, E., and Yew, D.T., Serotonin 5-HT2A and 5-HT6 receptors in the prefrontal cortex of Alzheimer and normal aging patients, BMC Neurosci., 2006, vol. 7, рр. 1–8. https://doi.org/10.1186/1471-2202-7-36CrossRef

32.

Yuede, C.M., Wallace, C.E., Davis, T.A., et al., Pimavanserin, a 5HT(2A) receptor inverse agonist, rapidly suppresses Aβ production and related pathology in a mouse model of Alzheimer’s disease, J. Neurochem., 2021, vol. 156, рр. 658–673. https://doi.org/10.1111/jnc.15260CrossRefPubMedPubMedCentral

33.

Solas, M., Van Dam, D, Janssens, J., et al., 5-HT(7) Receptors in Alzheimer’s disease, Neurochem. Int., 2021, vol. 150. https://doi.org/10.1016/j.neuint.2021.105185

34.

Molobekova, C.A., Kondaurova, E.M., Ilchibaeva, T.V., et al., Amisulpride decreases tau protein hyperphosphorylation in the brain of OXYS rats, Curr. Alzheimer Res., 2023. https://doi.org/10.2174/1567205020666230828144651

35.

Fidalgo, S., Ivanov, D.K., and Wood, S.H., Serotonin: From top to bottom, Biogerontology, 2013, vol. 14, pp. 21–45. https://doi.org/10.1007/s10522-012-9406-3CrossRefPubMed

36.

Madsen, K., Haahr, M.T., Marner, L., et al., Age and sex effects on 5-HT 4 receptors in the human brain: A 11 CSB207145 PET study, J. Cereb. Blood Flow Metab., 2011, vol. 31, p. 1475–1481. https://doi.org/10.1038/jcbfm.2011.11CrossRefPubMedPubMedCentral

37.

Rebholz, H., Friedman, E., and Castello, J., Alterations of expression of the serotonin 5-HT4 receptor in brain disorders, Int. J. Mol. Sci., 2018, vol. 19. https://doi.org/10.3390/ijms19113581

38.

Zhang, X.X., Tian, Y., Wang, Z.T., et al., The epidemiology of Alzheimer’s disease modifiable risk factors and prevention, J. Prev. Alzheimer’s Dis., 2021, vol. 8, pp. 313–321. https://doi.org/10.14283/JPAD.2021.15CrossRef

Titel: Patterns of Expression of the Key Genes of the BDNF System and Serotonin Receptors in the Brain of OXYS Rats in the Development of the Signs of Alzheimer’s Disease
verfasst von: M. Alsallum
Ya. P. Kaminskaya
A. S. Tsybko
N. G. Kolosova
V. S. Naumenko
Publikationsdatum: 15.02.2024
Verlag: Pleiades Publishing
Erschienen in: Advances in Gerontology / Ausgabe 2/2023
Print ISSN: 2079-0570
Elektronische ISSN: 2079-0589
DOI: https://doi.org/10.1134/S207905702360026X

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Patterns of Expression of the Key Genes of the BDNF System and Serotonin Receptors in the Brain of OXYS Rats in the Development of the Signs of Alzheimer’s Disease

Abstract

Leitlinien kompakt für die Allgemeinmedizin

Facharzt-Training Allgemeinmedizin

Neu im Fachgebiet Allgemeinmedizin

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Wie der Klimawandel gefährliche Pilzinfektionen begünstigt

So wirken verschiedene Alkoholika auf den Blutdruck

Das sind die führenden Symptome junger Darmkrebspatienten

Update Allgemeinmedizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2023

Influence of AMPK on the Functioning of the Circadian Clock and Its Possible Role in the Development of Age-Related Metabolic Disorders

Senolytic Drugs: Implications for Clinical Practice

Association between Telomere Length and Geriatric Status in Centenarians

Basic Epigenetic Mechanisms of Aging

Geroprotective Effect of the Mitochondrial-Targeted Antioxidant SkQBerb in a Model of the Chronological Aging of MB135 Human Myoblasts

Brain Aging

Leitlinien kompakt für die Allgemeinmedizin

Facharzt-Training Allgemeinmedizin

Neu im Fachgebiet Allgemeinmedizin

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Wie der Klimawandel gefährliche Pilzinfektionen begünstigt

So wirken verschiedene Alkoholika auf den Blutdruck

Das sind die führenden Symptome junger Darmkrebspatienten

Update Allgemeinmedizin